Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.
Who will be affected?
Readers: No access to all 28 journals. We recommend accessing our articles via PubMed Central
Authors: No access to the submission form or your user account.
Reviewers: No access to your user account. Please download manuscripts you are reviewing for offline reading before Wednesday, July 01, 2020 at 7:00 PM.
Editors: No access to your user account to assign reviewers or make decisions.
Copyeditors: No access to user account. Please download manuscripts you are copyediting before Wednesday, July 01, 2020 at 7:00 PM.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Leveraging patient-reported outcome measures for optimal dose selection in early phase cancer trials
Bill Byrom;
Anthony Everhart;
Paul Cordero;
Chris Garratt;
Tim Meyer
ABSTRACT
While patient-reported outcome measures (PROMs) are regularly incorporated into phase III clinical trials, there has been little use of PROMs in early phase trials [1]. However, the patient perspective is a vital element of fully understanding dose-toxicity and selecting an optimal dose. This viewpoint paper reviews the rationale for, and practical approach to, collection of patient-reported outcomes (PRO) data in early-phase oncology drug development, and the rationale for electronic collection.
Citation
Please cite as:
Byrom B, Everhart A, Cordero P, Garratt C, Meyer T
Leveraging Patient-Reported Outcome Measures for Optimal Dose Selection in Early Phase Cancer Trials